For research use only. Not for therapeutic Use.
Povorcitinib（Cat No.:I045096）is an oral, selective Janus kinase 1 (JAK1) inhibitor being developed for the treatment of inflammatory and autoimmune diseases. By targeting JAK1, Povorcitinib disrupts signaling pathways involved in cytokine-mediated inflammation, offering therapeutic potential in conditions such as atopic dermatitis, alopecia areata, hidradenitis suppurativa, and other chronic inflammatory disorders. Its selectivity for JAK1 aims to minimize off-target effects commonly associated with pan-JAK inhibitors, improving safety and tolerability. Povorcitinib is in clinical development and is supplied for research into JAK-STAT pathway modulation and immune-mediated disease therapy.
| CAS Number | 1637677-22-5 |
| Synonyms | 4-[3-(cyanomethyl)-3-[4-(3,5-dimethyl-1H-pyrazol-4-yl)pyrazol-1-yl]azetidin-1-yl]-2,5-difluoro-N-[(2S)-1,1,1-trifluoropropan-2-yl]benzamide |
| Molecular Formula | C23H22F5N7O |
| Purity | ≥95% |
| IUPAC Name | 4-[3-(cyanomethyl)-3-[4-(3,5-dimethyl-1H-pyrazol-4-yl)pyrazol-1-yl]azetidin-1-yl]-2,5-difluoro-N-[(2S)-1,1,1-trifluoropropan-2-yl]benzamide |
| InChI | InChI=1S/C23H22F5N7O/c1-12-20(13(2)33-32-12)15-8-30-35(9-15)22(4-5-29)10-34(11-22)19-7-17(24)16(6-18(19)25)21(36)31-14(3)23(26,27)28/h6-9,14H,4,10-11H2,1-3H3,(H,31,36)(H,32,33)/t14-/m0/s1 |
| InChIKey | MSGYSFWCPOBHEV-AWEZNQCLSA-N |
| SMILES | CC1=C(C(=NN1)C)C2=CN(N=C2)C3(CN(C3)C4=C(C=C(C(=C4)F)C(=O)N[C@@H](C)C(F)(F)F)F)CC#N |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
